We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Dyadic International Inc (DYAI) Common Stock USD0.001

Sell:$1.82 Buy:$1.89 Change: $0.16 (8.14%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$1.82
Buy:$1.89
Change: $0.16 (8.14%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$1.82
Buy:$1.89
Change: $0.16 (8.14%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Contact details

Address:
1044 NORTH U.S. HIGHWAY ONE, SUITE 201
JUPITER
33477
United States
Telephone:
+1 (561) 7438333
Website:
https://dyadic.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DYAI
ISIN:
US26745T1016
Market cap:
$58.29 million
Shares in issue:
29.59 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Mark Emalfarb
    President, Chief Executive Officer, Director
  • Ping Rawson
    Chief Financial Officer
  • Joseph Hazelton
    Chief Operating Officer
  • Ronen Tchelet
    Vice President of Research and Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.